Mankind Pharma Bets on AI to Accelerate Drug Discovery and Innovation

Mankind Pharma has partnered with Denovo Sciences to launch an Artificial Intelligence (AI)-powered drug discovery programme, highlighting the growing role of advanced technology in pharmaceutical research. The collaboration combines Mankind Pharma's research infrastructure, experimental capabilities and clinical validation expertise with Denovo Sciences' proprietary AI platform to speed up the early stages of drug development. Using a human-in-the-loop approach, the programme will integrate AI-based molecular analysis with continuous scientific validation, helping researchers identify promising drug candidates more accurately while reducing the time, cost and effort spent on compounds with a lower probability of clinical success. The initiative is expected to improve research efficiency, shorten drug discovery timelines and support the development of more effective and accessible therapies. The partnership also reflects the increasing adoption of AI across India's pharmaceutical industry, strengthening the country's capabilities in biotechnology, innovation and next-generation healthcare, while reinforcing its position as a global hub for pharmaceutical research and development. $MANKIND Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.